Literature DB >> 32207095

Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient.

Banchob Sripa1,2, Wunchana Seubwai3,2, Kulthida Vaeteewoottacharn4,2, Kanlayanee Sawanyawisuth4,2, Atit Silsirivanit4,2, Worasak Kaewkong2,5, Kanha Muisuk3,2, Paweena Dana4,2, Chatchai Phoomak4,2, Worachart Lert-Itthiporn4,2, Vor Luvira6, Chawalit Pairojkul1,2, Bin T Teh7, Sopit Wongkham4,2, Seiji Okada8, Yaovalux Chamgramol9,10.   

Abstract

Three cholangiocarcinoma (CCA) cell line-formerly named, M156, M213 and M214 have been intensively used with discrepancy of their tumor origins. They were assumed to be originated from three different donors without authentication. To verify the origins of these cell lines, the short tandem repeat (STR) analysis of the currently used cell lines, the cell stocks from the establisher and the primary tumor of a CCA patient were performed. Their phenotypic and genotypic originality were compared. The currently used 3 CCA cell lines exhibited similar STR as CCA patient ID-M213 indicating the same origin of these cells. The cell stocks from the establisher, however, revealed the same STR of M213 and M214 cells, but not M156. The misidentification of M214 and M156 is probably due to the mislabeling and cross-contamination of M213 cells during culture. These currently used cell lines were renamed as KKU-213A, -213B and -213C, for the formerly M213, M214 and M156 cells, respectively. These cell lines were established from a male with an intrahepatic mass-forming CCA stage-4B. The tumor was an adenosquamous carcinoma with the liver fluke ova granuloma in evidence. All cell lines had positive CK19 with differential CA19-9 expression. They exhibited aneuploidy karyotypes, distinct cell morphology, cell growth, cytogenetic characteristic and progressive phenotypes. KKU-213C formed a adenosquamous carcinoma, whereas KKU-213A and KKU-213B formed poorly- and well-differentiated squamous cell carcinomas in xenografted mice. mRNA microarray revealed different expression profiles among these three cell lines. The three cell lines have unique characteristics and may resemble the heterogeneity of tumor origin.

Entities:  

Keywords:  CK19; Cell line; Cholangiocarcinoma; Establishment; Liver fluke

Mesh:

Substances:

Year:  2020        PMID: 32207095     DOI: 10.1007/s13577-020-00334-w

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.174


  40 in total

1.  iNOS-dependent DNA damage via NF-kappaB expression in hamsters infected with Opisthorchis viverrini and its suppression by the antihelminthic drug praziquantel.

Authors:  Somchai Pinlaor; Yusuke Hiraku; Puangrat Yongvanit; Saeko Tada-Oikawa; Ning Ma; Porntip Pinlaor; Paiboon Sithithaworn; Banchob Sripa; Mariko Murata; Shinji Oikawa; Shosuke Kawanishi
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

2.  Whole-Genome and Epigenomic Landscapes of Etiologically Distinct Subtypes of Cholangiocarcinoma.

Authors:  Apinya Jusakul; Ioana Cutcutache; Chern Han Yong; Jing Quan Lim; Mi Ni Huang; Nisha Padmanabhan; Vishwa Nellore; Sarinya Kongpetch; Alvin Wei Tian Ng; Ley Moy Ng; Su Pin Choo; Swe Swe Myint; Raynoo Thanan; Sanjanaa Nagarajan; Weng Khong Lim; Cedric Chuan Young Ng; Arnoud Boot; Mo Liu; Choon Kiat Ong; Vikneswari Rajasegaran; Stefanus Lie; Alvin Soon Tiong Lim; Tse Hui Lim; Jing Tan; Jia Liang Loh; John R McPherson; Narong Khuntikeo; Vajaraphongsa Bhudhisawasdi; Puangrat Yongvanit; Sopit Wongkham; Yasushi Totoki; Hiromi Nakamura; Yasuhito Arai; Satoshi Yamasaki; Pierce Kah-Hoe Chow; Alexander Yaw Fui Chung; London Lucien Peng Jin Ooi; Kiat Hon Lim; Simona Dima; Dan G Duda; Irinel Popescu; Philippe Broet; Sen-Yung Hsieh; Ming-Chin Yu; Aldo Scarpa; Jiaming Lai; Di-Xian Luo; André Lopes Carvalho; André Luiz Vettore; Hyungjin Rhee; Young Nyun Park; Ludmil B Alexandrov; Raluca Gordân; Steven G Rozen; Tatsuhiro Shibata; Chawalit Pairojkul; Bin Tean Teh; Patrick Tan
Journal:  Cancer Discov       Date:  2017-06-30       Impact factor: 39.397

3.  Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia.

Authors:  Ahmad Ramzi Yusoff; Mohd Muzammil Abdul Razak; Boon Koon Yoong; R Vijeyasingam; Zuraidah Mahmud Siti
Journal:  World J Gastroenterol       Date:  2012-02-07       Impact factor: 5.742

4.  Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma.

Authors:  Natini Jinawath; Yaovalux Chamgramol; Yoichi Furukawa; Kazutaka Obama; Tatsuhiko Tsunoda; Banchob Sripa; Chawalit Pairojkul; Yusuke Nakamura
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

5.  Strong promoting effect of Opisthorchis viverrini infection on dimethylnitrosamine-initiated hamster liver.

Authors:  W Thamavit; C Pairojkul; D Tiwawech; T Shirai; N Ito
Journal:  Cancer Lett       Date:  1994-04-01       Impact factor: 8.679

Review 6.  Tumour heterogeneity and resistance to cancer therapies.

Authors:  Ibiayi Dagogo-Jack; Alice T Shaw
Journal:  Nat Rev Clin Oncol       Date:  2017-11-08       Impact factor: 66.675

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

8.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

9.  Increased nitrosamine and nitrate biosynthesis mediated by nitric oxide synthase induced in hamsters infected with liver fluke (Opisthorchis viverrini).

Authors:  H Ohshima; T Y Bandaletova; I Brouet; H Bartsch; G Kirby; F Ogunbiyi; V Vatanasapt; V Pipitgool
Journal:  Carcinogenesis       Date:  1994-02       Impact factor: 4.944

Review 10.  Risk factors for cholangiocarcinoma.

Authors:  Tamir Ben-Menachem
Journal:  Eur J Gastroenterol Hepatol       Date:  2007-08       Impact factor: 2.566

View more
  27 in total

1.  Aberrant GLUT1 Expression Is Associated With Carcinogenesis and Progression of Liver Fluke-associated Cholangiocarcinoma.

Authors:  Ubonrat Thamrongwaranggoon; Sakkarn Sangkhamanon; Wunchana Seubwai; Paksiree Saranaruk; Ubon Cha'on; Sopit Wongkham
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

2.  NF-κB and STAT3 co-operation enhances high glucose induced aggressiveness of cholangiocarcinoma cells.

Authors:  Charupong Saengboonmee; Chatchai Phoomak; Suangson Supabphol; Kyle R Covington; Oliver Hampton; Chaisiri Wongkham; Richard A Gibbs; Kazuo Umezawa; Wunchana Seubwai; Marie-Claude Gingras; Sopit Wongkham
Journal:  Life Sci       Date:  2020-10-07       Impact factor: 5.037

3.  Comprehensive drug response profiling and pan-omic analysis identified therapeutic candidates and prognostic biomarkers for Asian cholangiocarcinoma.

Authors:  Supawan Jamnongsong; Patipark Kueanjinda; Pongsakorn Buraphat; Phuwanat Sakornsakolpat; Kulthida Vaeteewoottacharn; Seiji Okada; Siwanon Jirawatnotai; Somponnat Sampattavanich
Journal:  iScience       Date:  2022-09-23

4.  Piperlongumine and bortezomib synergically inhibit cholangiocarcinoma via ER stress-induced cell death.

Authors:  Narathip Naradun; Krajang Talabnin; Kanyavee Issarangkul Na Ayuttha; Chutima Talabnin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-13       Impact factor: 3.195

5.  Emerging roles of GALNT5 on promoting EGFR activation in cholangiocarcinoma: a mechanistic insight.

Authors:  Marutpong Detarya; Worachart Lert-Itthiporn; Panupong Mahalapbutr; Methus Klaewkla; Supannika Sorin; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Wunchana Seubwai; Chaisiri Wongkham; Norie Araki; Sopit Wongkham
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

Review 6.  Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines.

Authors:  Abdulkadir Isidan; Ali Yenigun; Daiki Soma; Eric Aksu; Kevin Lopez; Yujin Park; Arthur Cross-Najafi; Ping Li; Debjyoti Kundu; Michael G House; Sanjukta Chakraborty; Shannon Glaser; Lindsey Kennedy; Heather Francis; Wenjun Zhang; Gianfranco Alpini; Burcin Ekser
Journal:  Am J Pathol       Date:  2022-05-28       Impact factor: 5.770

7.  Bioinformatic Prediction of Signaling Pathways for Apurinic/Apyrimidinic Endodeoxyribonuclease 1 (APEX1) and Its Role in Cholangiocarcinoma Cells.

Authors:  Doungdean Tummanatsakun; Tanakorn Proungvitaya; Sittiruk Roytrakul; Siriporn Proungvitaya
Journal:  Molecules       Date:  2021-04-29       Impact factor: 4.411

8.  Role of laminin and cognate receptors in cholangiocarcinoma cell migration.

Authors:  Kittiya Islam; Parichut Thummarati; Pakkanun Kaewkong; Banchob Sripa; Tuangporn Suthiphongchai
Journal:  Cell Adh Migr       Date:  2021-12       Impact factor: 3.405

9.  A Novel Serum Glycobiomarker for Diagnosis and Prognosis of Cholangiocarcinoma Detected by Butea monosperma Agglutinin.

Authors:  Karuntarat Teeravirote; Sukanya Luang; Sakda Waraasawapati; Patcharee Boonsiri; Chaisiri Wongkham; Sopit Wongkham; Atit Silsirivanit
Journal:  Molecules       Date:  2021-05-08       Impact factor: 4.411

10.  Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo.

Authors:  Jeerati Prompipak; Thanaset Senawong; Banchob Sripa; Albert J Ketterman; Suppawit Utaiwat; Khanutsanan Woranam; Jarckrit Jeeunngoi; Gulsiri Senawong
Journal:  Sci Rep       Date:  2021-07-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.